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Introduction 
Yakshma, a disease of ancient origin described 
in Vedic medicine, could be correlated well with 
Tuberculosis. This belief-based concept seems to have 
been well ruminated upon, and eventually entered 
reason-based Ayurvedic treatises with a redefined 
name Rajayakshma (Pulmonary tuberculosis -PTB). 
Many religious, mythological and historical episodes 
are linked with these dreadful diseases. Rajayakshma 
(PTB) is considered to be a disease of grave prognosis 
along with Udara (ascites) and Balashosha (marasmus).
(1) Pulmonary tuberculosis remains a major public 
health problem in developing countries. Tuberculosis is 
caused by infection with Mycobacterium Tuberculosis 
(MTB), which is part of a complex of organisms 
including Mycobacterium bovis (reservoir cattle) and 
Mycobacterium africanum (reservoir human).  
Special study conducted by WHO estimated 
that about 1/3rd world’s population is infected by 
Mycobacterium tuberculosis. It kills more adults in 
India than any other infectious diseases. Hence, it’s a 
major barrier for socioeconomic development of India. 
Keeping all this in mind government has developed 
Revised National Tuberculosis Control Programme, 
which includes DOTS. It is the main weapon to combat 
TB today. The main target of this program is 85% cure 
rate and 70% case detection rate. Since 2007, India has 
achieved this global target of cure rate and case 
detection rate. Furthermore, RNTCP has 100% 
coverage rate under DOTS. In 2018, India was able to 
achieve a Total Notification of 21.5 Lakh TB cases of 
which 25 % was from the private sector. Majority of the 
TB burden is among the working age group. The 89% 
of TB cases come from the age group of 15-69 years. 
About 2/3 of the TB cases are Males. Uttar Pradesh, 
with 17% of population of the country, is the largest 
contributor to the TB cases in with 20% of the total 
notifications, accounting to about 4.2 Lakh cases (187 
cases/ lakh population).(2) 
In Rajayakshma (PTB), Dhatukshaya (tissue 
emaciation or loss) is universally accepted as one of the 
main reasons to initiate pathogenesis. And there is 
inevitable metabolic dysfunction (Dhatwagni nashana), 
out of which rasa (tissue fluid), rakta (blood), mansa 
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(muscle), meda (adipose tissue) and sukra (generative 
tissue) are lost. Ultimately, deterioration of immunity 
(ojokshaya) is evident. In tuberculosis starting 
from Ojokshaya, sukra, meda dhatus to rasa dhatu is 
lost preceding each other, which is known 
as Pratilomakshaya and is an unusual metabolic 
change.(3) 
Many herbal and herbo-mineral drugs are being 
used for the treatment of Rajayakshma (PTB). Similarly, 
there is one drug named Rudanti (Capparis moonii 
wight.) which is widely used as an anti-tubercular drug, 
but till now no proper research has been done to 
evaluate the probable mode of its action. But many in-
vitro and in-vivo studies have been done which shows 
that it has an immunomodulatory(4) and anti-oxidant(5) 
properties along with its hepato protective activity. In 
India more than 80 % population depends upon 
traditional healing therapy. Recently Ministry of 
AYUSH and Ministry of Health & Family Welfare have 
signed MoU to forge inter-sectoral convergence at the 
level of policy, planning and program implementation 
for accelerated response towards “Tuberculosis Free 
India” initiative.(6) 
Poor drug compliance by patients being one of 
the foremost reasons for frequent relapses and bacterial 
resistance. Also due to its longer duration and many 
side effects, it is necessary to develop an adjuvant 
therapy which will minimize the hazards and help 
patient to improve the immune status. So present study 
was intended to evaluate the rasayaṇa effect of Rudanti 
(Capparis moonii wight.) as an adjunct to anti-
tubercular drugs in the management of Rajayakṣma 
(PTB).  
Materials  
Drug 
Rudanti (Capparis moonii wight.) which is 
widely used as an anti-tubercular drug Rudanti first 
came into reference in soḍhala nighaṇṭu as 
Vriddhapalitake.(7) Later a detailed description was 
mentioned in Raja nighaṇṭu. Rudanti has katu-tikta 
rasa, ushna virya, anti-tubercular, anti-microbial, 
raktapittanashana, properties, anti-asthmatic, 
expectorant, anti-diabetic and Rasayaṇa actions.(8)  
Capparis moonii, Wight belongs to the family 
Capparidaceae frequently found in the konkana regions 
and grows vigorously in hot semi-arid conditions. Its 
worldwide distribution is restricted to only Indian 
Subcontinent i.e. southern India, Sri Lanka exhibiting 
its endemism.(5) 
Collection of Drug 
Trial drug i.e. Rudanti (Capparis moonii 
Wight.) unripe fruits were collected from the forest of 
Dist. Sindhudurg, State- Maharashtra in the month of 
May-June-2018. These fruits were sliced in to small 
pieces dried in the shade and transported to Varanasi. 
Identification 
Botanical Identification of the trial drug was 
done by Professor Kamal Nayan Dwivedi, Department 
of Dravyaguna, Faculty of Ayurveda, IMS, BHU. 
Sample of collected raw drug was kept in the museum 
of the department of Dravyaguna with specimen 
accession number DG/19-20/234. 
Preparation of Trial Drug 
Completely dried pieces of unripe Rudanti 
(Capparis moonii Wight.) fruits were grinded into fine 
powder of light salmon colour. The advantage of churna 
kalpana is that, smaller particle size of powder 
facilitates rapid absorption of drug that leads to higher 
concentration of drug in the blood in a shorter time 
thereby the action is produced in a lesser time. This 
powder was then packed into airtight polybags each 
packet weighed approx. 300 gms. 
Methods 
CTRI Registration 
 This clinical study was registered under the 
Clinical Trials Registry- India (CTRI), hosted at the 
ICMR's National Institute of Medical Statistics with 
CTRI/2018/08/015173 register number. 
Ethical consideration 
The study was conducted with good clinical 
practice and confirmed by the approval of the Institute 
ethical committee with letter number Dean/2018/EC/
702, dated 14.02.2018. 
Study Design 
It is a single blind therapeutic control 
randomized clinical trial consisting of 100 newly 
diagnosed or relapsed cases of pulmonary tuberculosis 
patients from both the sexes aged between 20 and 70 
years and randomly divided into two groups irrespective 
of age, sex and religion.  
Patients attending the O.P.D. and I.P.D. of TB 
and Chest department and dravyaguṇa of S.S. Hospital, 
Varanasi, were randomly selected for the study, 
irrespective of age, sex, religion, occupation etc. As per 
the Performa, detailed history and clinical examination 
and investigation were done and recorded. Subjects 
were formally informed about the study and those who 
give written informed consent were enrolled and 
randomly allotted to the study groups. 
Group A: Therapeutic control group (CG)- 50 patients 
were treated with DOTS.  
Group B: Test group (TG) - 50 patients treated with 
DOTS along with Rudanti powder. 
Drug:  Rudanti (Capparis moonii Wight.) 
Dosage form: Powder 
Dose:   5 grams BD 
Duration of treatment: 6 months (180 days). 
Follow up: 3 follow ups after every 30 days. 
Table 1 Inclusion and Exclusion criteria 
Inclusion Criteria Exclusion criteria
i) Cases of sputum -ve 
and sputum +ve
i) E x t r a p u l m o n a r y 
tuberculosis
ii) Relapse cases ii) HIV and Tuberculosis 
co-infect
iii) Failure cases iii) MDR Tuberculosis 
patients
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Criteria for assessment 
Subjective criteria 
Most of the symptoms and s igns of 
Rajayakshma (PTB) described in Ayurveda are 
subjective in nature. Following symptoms were taken 
jwara (Fever), swasa (Dyspnea), kasa (Cough), 
parshwashool (Pain in the ribs), raktashthivana 
(Hemoptysis), swarabheda (Hoarseness of voice), 
atisara (Diarrhea), aruchi (Anorexia), daurbalaya 
(Weakness). To give results objectively and for 
statistical analysis, (Normal-0, Mild-1, Moderate-2, 
Severe-3) scoring pattern was adopted. This score was 
obtained before and after interval of every month till the 
end of treatment through statistical analysis and 
percentage relief was taken out to assess the efficacy of 
therapy. 
Objective Criteria 
It was assessed on the basis of Body weight and 
Biochemical investigations (CBC, LFT, RFT, Blood 
sugar fasting and post prandial, Total Protein, serum 
albumin, HIV, Pregnancy, sputum for AFB, CBNAAT, 
Liquid culture). Chest X-ray done before during and at 
the end of the treatment with the follow-up for 3 month 
in terms of percentage relief and statistical evaluations 
Clinical improvement:  
Data obtained from the parameters of 
assessment, before, during & after the treatment was 
utilised to evaluate the overall effect of therapy. 
Statistical Analysis 
Paired t-test is used to find out the significant 
changes from initial to different follow ups and between 
the follow-ups for within the group comparison test 
Friedman test was done. X2-test was used to find out the 
significant difference in the quantitative variables 
among the study groups. Z- test was applied to find out 
the significant changes from baseline to different follow 
ups and between the follow ups. 
Observations and Results  
The demographic data in relation to sex, age, 
socio-economic status and observations on subjective 
parameters and objective parameters were presented in 
the 
Table 2 indicates that the incidence rate ratio by 
gender out of the 100 pulmonary tuberculosis patients 
38 % was women cases and 62 % were men. 
Table 2 Gender ratio in the groups 
Table 3 indicate the out of the total, 100 cases 
(65 %) belong to age group below 40 years. This 
observation supports the knowledge that pulmonary TB 
(PTB) is commonly a disease of the young adults. 
         
Table 3 Age group ratio 
Table 4 shows socio-economic status has 
momentous role in the causation of disease. It is fairly 
clear that almost 100% of the cases belong to the lower 
and middle class. These ratios may vary in other 
studies, since this study was conducted SSL hospital, 
BHU most of the visiting patients belongs to lower and 
middle class population, the ability of whom to afford 
private care is compromised. 
Table 4 Socioeconomic ratio 
Among the observed 9 symptoms kasa (Cough) 
was having highest incidence rate (99 %), whereas 
atisara (diarrhea) had the lowest incidence rate (0%). 
Incidence rate of all the nine symptoms were given in 
table 5. 
Table 5 Incidence of Clinical Features  
n= Number of patients. 
Among the 9 subjective symptoms, the 
percentage of relief in the daurbalaya (Weakness) was 
97.91 % in the CG whereas in TG it was 100 %, after 
completion of six month trial and in rest of the 
subjective parameters percentage of relief was 100 % in 
both the groups so there is no significant difference 
between the two groups. But when we analyze the 
percentage of relief after 3 months of treatment there 
was a significant difference between the group 
especially in the symptoms of kasa (CG 50 % and TG 
100 %) and daurbalaya (CG 64.58 % and TG 100 %). 
Data of all the subjective parameters are shown in table 
6. 
iv) Age 20-70 year iv) Age below 20 year 
and above 70 year
V) With mild pulmonary 
infusion
V) Severely ill and 
Pregnant patients
Group I Group II
Male 31 31
Female 19 19
Age Group Group I Group II
20-29 yrs 14 29
30-39 yrs 14 8
40-49 yrs 5 4
50-59 yrs 9 5
60-69 yrs 8 4
Socio-economic 
Status Group I Group II
Lower 19 18
Middle 31 32
Upper 0 0
Symptoms Group I (n)
Group II 
(n) Percentage
Jwara 45 44 89
Swasa 43 45 88
Kasa 50 49 99
Parshwashool 44 43 87
Raktakshtivna 20 15 35
Swarabheda 9 15 24
Atisara 0 0 0
Aruchi 47 49 96
Daurbalaya 48 49 97
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Table 6- %age of relief after 3 and 6 months of treatment 
n= Number of patients. 
In the investigations of haemoglobin (Fig 1) 
there was highly significant difference found between 
the groups (t=4.831, p=0.000) after 6 months of 
treatment. In the TG mean haemoglobin before and 
after treatment was 11.57 g/dl and 13.10 g/dl (difference 
of 1.53 g/dl) whereas in CG it was 11.25 g/dl and 12.02 
g/dl (difference of 0.77 g/dl).  
Fig 1- Mean Value of Haemoglobin (g/dl) 
 
BT (Before start of Treatment), F1 (3 months after 
the start Treatment), F2 (6 months after the start of 
treatment) 
In the TG mean TLC before and after treatment 
was 9889.20 and 5408.00 (difference of 4481.20) 
whereas in CG it was 9320.80 and 5822.00 (difference 
of 3498.8) which shows that there was considerable 
decrease in TLC counts in patients of TG which was 
also statistically significant (t=2.137, p=0.035).(Fig 2) 
Fig 2- Mean Value of Total Leukocyte Count (TLC) 
BT (Before start of Treatment), F1 (3 months after 
the start Treatment), F2 (6 months after the start of 
treatment) 
In the TG mean BMI before and after treatment 
was 19.76 and 22.34 (difference of 2.58) whereas in CG 
it was 19.36 and 21.31 (difference of 1.95) which shows 
that there was statistically significant improvement in 
BMI in TG patients (t= 2.316, p= 0.023).(Fig 3) 
Fig 3- Mean Value of Body Mass index (BMI) 
 
BT (Before start of Treatment), F1 to F8 
(1,2,3,4,5,6,7,8 months after the start of treatment) 
In both groups all patients were reported with 
sputum conversion within the stipulated time i.e. after 
intensive phase of treatment of two months HRZE 
(H-Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: 
Ethambutol). Significant improvement in the chest x-
rays was found after the completion of six month 
treatment in both groups. 
Drug induced liver injury is a major concern 
during the treatment of pulmonary tuberculosis in this 
trial 5 patients (10 %) from CG were found to have 
increased levels in serum bilirubin and other liver 
enzymes, when compared to the TG only 1 patient (2 
%) had disturbed liver function test. These results 
matches with the other diverse studies which states that 
overall risk of drug induced liver injury in TB ranges 
from 5 to as high as 33%. (9) 
Discussion 
Rajayakshma (PTB) is described in Ayurveda 
with specific reference to etiology (Nidana Chatushka) 
and symptomatology. These correspond to the clinical 
experience in PTB. The Lakshanas of Kaphaja Krimi 
(mucosal bacteria) seems to resemble Mycobacterium 
Symptoms
Group I CG Group II TG
At 3 
months 
n= AT/
BT
% 0f 
Relief
At 6 
months 
n= AT/
BT
% 0f 
Relief
At 3 
months 
n= AT/
BT
% 0f 
Relief
At 6 
months 
n= AT/
BT
% 0f 
Relief
1 Jwara 41/45 91.11 45/45 100 44/44 100 44/44 100
2 Swasa 39/43 90.69 43/43 100 45/45 100 45/45 100
3 Kasa 25/50 50 50/50 100 49/49 100 49/49 100
4 Parshwashool 44/44 100 44/44 100 42/43 97.67 43/43 100
5 Raktakshtivna 18/20 90 20/20 100 15/15 100 15/15 100
6 Swarabheda 08/09 88.88 09/09 100 15/15 100 15/15 100
7 Atisara 00/00 - 00/00 - 00/00 - 00/00 -
8 Aruchi 42/47 89.36 47/47 100 49/49 100 49/49 100
9 Daurbalaya 31/48 64.58 47/48 97.91 49/49 100 49/49 100
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tuberculosis and its effect on the patient.(10) The drug 
Rudanti possess properties of Rasayana,(11) Krimighna 
(anti-bacterial) and Kshayahara.(8) The purpose of 
selecting Rudanti to check its Rasayana activity was 
fulfilled by these criteria. 
Jwara (Pyrexia): There was complete 
abatement of febrile morbidity in TG patients with in 
the 30 days of treatment whereas in the CG 42.22 % of 
patients got relieved of fever. More than 90 % of cases 
got relieved after 90 days of treatment in CG.  
Swasa (Dyspnea): In the first 30 days there 
was 95.55 % relief in symptoms of dyspnea in the TG 
patients whereas in the CG 34.88 % of patients got 
relief. More than 90 % of cases got relieved after 90 
days of treatment in CG. 
Kasa (Cough): In the first 30 days there was 
71.42 % relief in cough gradually diminished and 
ultimately became occasional and non-productive with 
easy expectoration within the 60 days of treatment in 
TG patients, whereas in CG no relief was observed in 
first 30 days of treatment More than 90 % of cases got 
relieved after 60 days of treatment in TG and for the 
same number in CG it took 120 days of treatment. 
Parshwashool (Pain in costal and scapular 
region): There was 90.69 % of relief in symptom 
observed in TG patients with in the 30 days of treatment 
and 100 % after 60 days, whereas in CG 9.09 % of 
relief symptom was observed in 30 days and 100 % 
after 90 days.  
Raktakshtivna (Haemoptysis): There was 
complete abatement of haemoptysis in TG patients with 
in the 30 days of treatment whereas in the CG 50 % of 
patients got relieved in the same time. More than 90 % 
of cases got relieved after 90 days of treatment in CG.  
Swarabheda (Hoarseness of voice): There was 
93.33 % of relief in symptom observed in TG patients 
with in the 30 days of treatment and 100 % relief was 
observed after 60 days, whereas in CG 12.5 % of relief 
in symptom was observed in 30 days and more than 90 
% was observed after 90 days. Better relief in TG 
patients can be attributed to the lessening of cough and 
easy expectoration within 30 days.  
Atisara (Diarrhea): Not a single patient has 
reported diarrhea during the treatment. 
Aruchi (Anorexia): There was 91.83 % of 
relief in symptom observed in TG patients with in the 
30 days of treatment and 100 % relief was observed 
after 60 days, whereas in CG 2.12 % of relief in 
symptom was observed in 30 days and more than 90 % 
was observed after 120 days. 
Daurbalaya (Weakness): There was 79.59 % 
of relief in symptom observed in TG patients with in the 
30 days of treatment and 100 % relief was observed 
after 60 days, whereas in CG 4.16 % of relief in 
symptom was observed in 30 days and more than 90 % 
was observed after 120 days. Improve in appetite and 
increase in weight of the patients in TG is mainly 
account for gaining strength.  
Probable mode of action 
Basic science research reveals that Rudanti 
( C a p p a r i s m o o n i i W i g h t . ) p o s s e s s e s 
immunomodulatory (4) and antioxidant(5) properties. 
Immunomodulation through stimulation or suppression 
may help in maintaining a disease free state. Agents that 
activate host defense mechanisms in the presence of an 
impaired immune responsiveness can provide 
supportive therapy to conventional chemotherapy. Thus 
Rudanti improves immunity and enhances the defensive 
mechanism of the body. Stimulation of the Reticulo 
Endothelial System (RES) activates the mesenchyme 
and accelerates healing at the tubercular sites. In turn, 
this process results in destruction of killer cells and 
formation of new healthy tissue.(9) 
Addition of Rudanti powder to DOTS offers 
hepatoprotection(12) due to the presence of β-sitosterol 
and Rutin and components like stachyhydrin,(14) 
chebulinic acid derivatives and gallotannins reported for 
antitussive, antibacterial properties.(13) It has 
immunomodulatory properties, which create the 
subjective well-being and cause remarkable changes in 
the objective parameters.  
In patients of Tuberculosis which can be 
compared with Rajayakshma, there are 3 major events 
occurring viz. Srotorodh, Rasaraktadi Dhatukshaya and 
Dhatwagnimandya. Rudanti Choorna is kashaya, tikta 
in rasa (taste), laghu tikshna guna, katu vipaka and 
ushna virya which help in removing the srotorodh and 
dhatwagnimandya, which provided proper nourishment 
of Dhatus also it is having Rasayana properties which 
help in building up of superior dhatus. Moreover it is 
also useful in associated symptoms of Rajayakshma like 
Kasa (Cough), shwasa (Dyspnea), raktapitta 
(Hemorrhagic conditions) and showed action 
fantastically. 
Further due to proper nourishment of all Dhatus 
‘Shukra’ is properly formed and thus Vyadhikshamatwa 
was improved. Rasayan effect helped patient to combat 
disease and enhanced proper and early recovery. 
Limitations 
Due to the limitation of funds necessary bio 
markers like Tumour necrosis factor- alfa and inter 
leukin 6 was not taken in to consideration and also 
sample size was small. 
Recommendations 
As in in-vivo studies Rudanti shows 
immunomodulatory and antioxidant properties and in 
clinical study test group patients shows better increase 
in BMI when compare to control group, so a study 
should be done by taking bio markers like Tumour 
necrosis factor- alfa and inter leukin 6 in to 
consideration with large sample size. 
Conclusions 
This study shows that by incorporating an 
herbal rejuvenative in the management of PTB, a 
chronic debilitating disorder, had an additive effect. 
Rasayana, plays a supportive and adjuvant role in the 
management of communicable diseases. Utilization of 
this modality in the practice of modern medicine 
appears to be minimal. It is the ardent hope of the 
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participants of this study that mainstream medicine will 
give serious consideration to the availability of other 
such herb in the vast Pharmacopoeia of Ayurveda, 
which can substantially enhance the effect of the drugs 
in its collection. 
The purpose of this supportive therapy is to 
improve the defiance of the patient to damage caused by 
the tubercle bacilli, and to create an environment in the 
body unsuitable for proliferation of the bacilli. 
The aforesaid properties of the Rudanti are 
invaluable, not only for correcting low vitality state, but 
also in the treatment of the disease. Rudanti powder can 
be easily administered as an adjunct to DOTS. Rudanti 
has hepatoprotective properties, which remunerate the 
hepatotoxicity known to cause by DOTS drugs. 
Improved weight gain in TG patients in comparison to 
CG indicates the accessory effect of Rudanti.  
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